Chinese biotech is emerging as a significant sector of global innovation and collaboration, even as tensions persist between the United States and China over trade and security issues. Ahead of a scheduled meeting in Washington between Chinese President Xi Jinping and former U.S. President Donald Trump, industry observers suggest that biotech could be one area where both sides might ease their disputes.

So far this year, licensing agreements connected to Chinese biotech have reached a potential value of $110 billion worldwide, provided all contractual milestones are met. This figure represents a roughly $20 billion increase compared to last year, underscoring growing international interest in China's pharmaceutical research and development capabilities. These deals typically grant rights to manufacture and market treatments or technologies within designated regions. AstraZeneca stands out as a major player, having secured approximately $45 billion in licensing and research agreements since 2021 and announcing plans to invest an additional $15 billion in China by 2030.

The commercial rationale hinges on the global nature of medical needs. Diseases addressed by Chinese biotech innovations affect populations worldwide, and the sector is noted for rapid advancements, particularly in emerging therapeutic areas. Clinical trials in China benefit from accelerated patient recruitment—up to five times faster than counterparts in Western countries, according to consultancy McKinsey—facilitating quicker development timelines.

Despite these advantages, U.S. policymakers have expressed concerns about the outflow of capital and technology to China. Last year, Trump signed the Biosecurity Act into law, designed to restrict U.S. involvement with Chinese biotech firms amid fears of potential military connections or risks to sensitive intellectual property. One such company, WuXi App Tec, was blacklisted for alleged military ties, though a federal judge has since blocked that decision. Additional legislation targeting biotech collaborations is under consideration in the U.S. Congress.

However, many analysts argue that attempts to curb engagement with China’s biotech industry may be impractical and counterproductive. Unlike sectors such as semiconductor manufacturing, where components can be withheld, China is regarded as largely self-reliant in biotech, possessing an integrated ecosystem from raw materials and scientific expertise to manufacturing capabilities. The country also enjoys strong capital access through domestic and international markets, including Hong Kong, supported by government initiatives aiming to have China develop at least 25% of the world’s first-in-class drugs.

Critics of protectionism in this field note that while other products like automobiles and electronics can be sourced domestically in the U.S., access to innovative medical treatments is a different matter. Restricting collaboration could delay or deny patients worldwide access to breakthrough therapies. Advocates suggest that if Chinese research laboratories produce effective new treatments and technologies, the global community should welcome these advances irrespective of geopolitical rivalries.

As the two nations prepare for dialogue, biotech represents a complex intersection of competition and cooperation, highlighting the challenges of balancing national security concerns with the imperative to advance global health.